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Background: a single base pair deletion/insertion (4G/5G) polymorphism in the plasminogen activator inhibitor (PAI-1)
promoter appears to influence PAI-1 synthesis (increased PAI-1 and inhibition of fibrinolysis with the 4G allele) and
survival after severe trauma.
Objective: to identify whether the 4G/5G polymorphism influences the natural history of abdominal aortic aneurysm
(AAA).
Methods: Four hundred and sixty patients with small AAA were genotyped for the 4G/5G polymorphism. AAA growth
was assessed from serial ultrasonographic measurements, subject to linear regression analysis. Mortality following eventual
elective surgery was recorded.
Results: the frequency of the 3 genotypes (4G4G, 4G5G and 5G5G) was in Hardy±Weinberg equilibrium and similar to
that in a healthy population. The mean aneurysm growth rate was 0.37, 0.35 and 0.44 cm/year respectively for patients of
4G4G, 4G5G and 5G5G genotype respectively, p 0.07. The 30d mortality following open elective aneurysm repair was
8% (7/87), 8% (11/145) and 0% (0/56) for patients of 4G4G, 4G5G and 5G5G genotype respectively, giving a higher
mortality for those carrying a 4G allele p 0.03.
Conclusions: polymorphism of the PAI-1 gene promoter does not influence the development of AAA, although AAA
growth is faster for patients of 5G5G genotype. However, this genotype (5G5G), which is associated with enhanced
fibrinolysis, appears protective following open aneurysm repair. This effect of PAI-1 genotype on survival following surgery
is likely to have widespread significance in vascular and general surgery.
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Abdominal aortic aneurysm (AAA) is a common de-
generative vascular disease, in which genetic factors
are likely to influence the development of the aneur-
ysm. Screening studies have demonstrated that 20±
30% of brothers of a patient with AAA had an occult
AAA.1 The prevalence of AAA in a sibling of a patient
with AAA is 4 times the prevalence in siblings of
patients without AAA.2 Aortic aneurysms also are
characteristic of two monogenic disorders, Marfan
syndrome and Ehlers Danlos syndrome IV, where
the underlying mutations are in the fibrillin-1 and
type III procollagen genes respectively.3,4 There is* Please address all correspondence to: J. Powell, University Hospi-
tals of Coventry & Warwickshire, Clifford Bridge Road, Walsgrave,
Coventry CV2 2DX, U.K.
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genes underlie the common form of AAA found in
older people. Several studies have examined whether
the frequency of polymorphisms in other candidate
genes is different for patients with AAA compared
with healthy populations.5,6 The finding that a poly-
morphism in the interleukin-6 gene promoter was
associated with the survival of patients with small
AAA has prompted a debate on whether single
nucleotide polymorphisms can predict outcome in
polygenic traits.7,8
Interleukin-6 is an inflammatory marker. Inflamma-
tion and proteolysis appear to be the key pathological
processes underlying the aneurysmal degeneration
of the aortic wall.8 The matrix metalloproteinases
(MMPs) appear to have an important role in the de-
gradation of the extracellular matrix proteins, whichl rights reserved.
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MMP activity is complex and takes place both at the
transcriptional and posttranscriptional levels. MMPs
are secreted in a latent form requiring activation for
proteolytic activity. Studies in mice have suggested
that the urokinase-type plasminogen activator (uPA)/
plasmin system is a pathophysiologically significant
activator of proMMPs.9 Thinning and destruction of
the aortic media in apolipoprotein E deficient mice
results in aneurysm formation, which can be avoided
following targeted deletion of the uPA gene.9 Here
the underlying mechanism appeared to be limitation
of plasmin-dependent activation of metalloprotein-
ases.9 The corollary of this situation has been observed
in aortic xenografts, where overexpression of tissue
plasminogen activator inhibitor-1 (PAI-1) prevented
aneurysmal dilatation of the xenografts.10
The frequency and role of a single nucleotide poly-
morphism in the PAI-1 gene for patients with AAA
has been investigated recently in a cohort of 190 pat-
ients with AAA.11 Among these patients 39/190
(21%) had a strong family history of AAA. In these
39 patients there was a higher frequency of the
ÿ675 5G insertion allele of the 4G4 5G polymorph-
ism. This polymorphism is associated with altered
protein transcription, with greater amounts of PAI-1
being generated from the 4G allele compared to the 5G
allele.12 Hence, the possibility arises that there
might be less activation of MMPs and slower aneur-
ysm growth rates in patients carrying the 4G allele.
Therefore, we wished to test the hypothesis that
the growth rate of small AAAs would be faster for
patients of 5G genotype. For this purpose we studied
patients enrolled in the surveillance arm of the U.K.
Small Aneurysm Trial,13 for whom a genomic DNA
bank is available.
Patients and Methods
Patients
Patients studied, for aneurysm growth and survival,
were randomised to ultrasound surveillance as part
of the U.K. Small Aneurysm Trial.13 Briefly, patients
aged 60±76 years with asymptomatic AAA 4.0±
5.5 cm in diameter were randomised to either early
elective surgery or a period of ultrasound surveil-
lance. Patients in the surveillance arm (n 527) had
their aortic diameter measured either every 6 months
(AAA 4.0±4.9 cm) or every 3 months (AAA 5.0±
5.5 cm). When aneurysm diameter exceeded 5.5 cm,
aneurysm growth rate exceeded 1 cm/year or the
aneurysm became tender, surgery was recommended.Eur J Vasc Endovasc Surg Vol 23, May 2002All patients were `flagged' with Office of National
Statistics (ONS), to obtain information for deaths
and cause of death. A baseline peripheral venous
blood sample was drawn to provide cells for the
extraction of DNA and plasma for the measurement
of cholesterol and cotinine (by radioimmunoassay).
Aneurysm growth rates were calculated from linear
regression analysis, using only patients with 3 or
more diameter measurements. The repeatability of
AAA diameter measurement was 0.2 cm.13
Genotyping
DNA was prepared from peripheral blood cells and
stored in 96-well arrays at ÿ20 C. The local Research
Ethics Committee has approved the use of this
DNA bank to investigate the natural history of AAA.
Genotyping was performed for the previously de-
scribed functional promoter deletion/insertion poly-
morphism, ÿ675 4G/5G in the PAI-1 gene.12 The DNA
was amplified by polymerase chain reaction (PCR).
Following PCR, genotypes were resolved using re-
striction endonuclease and subsequent separation
using Metaphor agarose gel electrophoresis.
Data analysis
All analyses were performed using STATA. All con-
tinuous variables (age, initial aneurysm diameter, an-
eurysm growth rates and plasma cholesterol) were
normally distributed. A chi-squared test was used to
compare the observed numbers of each genotype with
those expected for a population in Hardy±Weinberg
equilibrium and to assess the relationship between
genotype and post-operative mortality.
Results
The study group consisted of 460 patients (383 males
and 77 females) with available DNA samples, from
which the promoter region of the PAI-1 gene was
amplified successfully using the polymerase chain re-
action. Demographic data on the patients are shown
in Table 1. On entry to the study, all patients had
asymptomatic small AAAs, 4.0±5.5 cm in diameter.
The genotype distribution of the 4G4 5G PAI-1
polymorphism studied is shown in Table 2. The fre-
quency of the rare allele (5G-allele) was 0.43.
The genotype distribution was consistent with the
population being in Hardy±Weinberg equilibrium.
There was no association between 4G4 5G genotypes
Table 1. Demographic details of the 460 AAA patients.
Variable Mean s.d.
Age (years) 69 4
Gender 383 males
77 females
Initial AAA diam (cm) 4.6 0.4
AAA growth rate (cm/year) (n 446) 0.4 0.3
Cholesterol (mmol/L) 6.2 1.2
Systolic BP (mm Hg) 156 26
Diastolic BP (mm Hg) 87 13
FEV1 (L) 2.1 0.8
 In the remaining 24 patients there was insufficient surveillance to
permit calculation of AAA growth rates.
Table 2. Initial aneurysm diameter and aneurysm growth rate
according to genotype.
PAI-1 675 4G4 5G
n AAA diam
(cm)
mean s.d.
Growth rate
(cm/year)
mean s.d.
30-day mortality
deaths/repairs
(%)
4/4 142 4.6
0.4
0.37
0.23
7/87
8%
4/5 241 4.6
0.3
0.35
0.29
13/148
9%
5/5 77 4.7
0.4
0.44
0.36
1/57
2%
p 0.12 0.07 0.08z
py 0.08
 Not all patients underwent AAA repair.
y Adjusted for age, sex and initial aneurysm diameter.
z Analysis as 2 groups, 5G5G versus 4G5G  4G4G.
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duals homozygous for the PAI-1 5G-allele appeared
to have faster aneurysm growth, although this was
of borderline significance, p 0.07. Adjustment for
age, sex and initial AAA diameter did not alter this
borderline significance.
During the surveillance period the AAA grew to
> 5.5 cm in diameter in 270 patients, became symp-
tomatic in a further 10 patients and expanded by
more than 1 cm/year, ruptured or protocol was brea-
ched in a further 12 patients. These 292 patients
underwent open AAA repair. Of these 21/292 (7%)
died within 30 days of surgery. The 30-day mortality
was 8% (7/87), 9% (13/148) and 2% (1/57) for pat-
ients of 4G4G, 4G5G and 5G5G genotype respecti-
vely: patients carrying a 4G allele had an increased
risk of post-operative death, chi-squared p 0.08.
After exclusion of the 4 patients with ruptured aneur-
ysm, for the patients who underwent elective, open
aneurysm repair, the 30-day mortality was 8% (7/87),
% (11/145) and 0% (0/56) for patients of 4G4G, 4G5G
and 5G5G genotype respectively: patients carryinga 4G allele had an increased risk of post-operative
death, chi-squared (Fisher's exact) p 0.03.
Previously, we have identified lung function (FEV1)
and creatinine as risk factors for mortality after ele-
ctive aneurysm repair. In patients from the U.K. Small
Aneurysm Trial14 the mean (s.d.) baseline FEV1 was
2.2 0.7, 2.1 0.7 and 2.1 0.8 L respectively for
patients of 4G4G, 4G5G and 5G5G genotypes res-
pectively, ANOVA p 0.84. The mean (s.d.) baseline
creatinine was 106 25, 109 27 and 106 25mol/L
for patients of 4G4G, 4G5G and 5G5G genotypes res-
pectively, ANOVA p 0.28.
Discussion
The results presented here continue the debate of
whether single nucleotide polymorphisms are predi-
ctive of outcome for patients with AAA. The finding
that patients with the 5G5G PAI-1 genotype, that is
associated with lower transcription and plasma con-
centrations of the fibrinolytic inhibitor PAI-1, appear
to have a much lower operative mortality following
AAA repair is tantalising. This finding is consistent
with previous report that patients of the 5G5G geno-
type have a lower mortality following major
trauma.15 Equally, the borderline association of faster
AAA growth for this same genotype is tantalising.
The biological hypothesis that, for patients of 5G5G
genotype, the lower transcription and plasma levels
of PAI-1 promotes aneurysm expansion by ineffec-
tive inhibition of plasmin activation of MMPs is
very plausible. It will be difficult to find larger
studies, with reproducible measurements of AAA
growth, in which to confirm or refute these border-
line associations.
Genes involved in the breakdown of extracellular
matrix are likely to play a substantial role in the
development of abdominal aortic aneurysm. How-
ever, it is unclear whether proteolytic enzymes have
a causative role in the formation of AAA or whether
an increased expression of these genes merely reflects
ongoing remodelling. The fibrinolytic enzyme system
has been associated with AAA formation,16±18 and
fibrinolytic genes are overexpressed in the aortic
aneurysm wall.19 The PAI-1 4G4 5G promoter poly-
morphism has been shown to modulate the gene
expression of PAI-1. The stretch of 5Gs located at
position ÿ675 creates a binding site for a transcrip-
tional repressor that results in lower promoter activity
in vitro and in lower plasma levels in vivo.12,20 In
the present study, the 4G-allele, which is associated
with higher PAI-1 expression, was associated with
slower aneurysm growth. This finding is consistentEur J Vasc Endovasc Surg Vol 23, May 2002
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active MMPs into active proteases. The frequency of
the 4G/5G polymorphism has previously been stu-
died in aneurysm cohorts. In a small study performed
on 47 AAA patients, 57 patients with intracranial
aneuryms and 165 controls, the allele-frequency did
not differ.21 In a second study, 190 patients with
AAA, including 39 patients with strong family his-
tories, and 163 controls were examined.11 The fre-
quencies of the 4G-allele were 0.59, 0.47, 0.62 and
0.61 for all patients, patients with familial history,
patients with no familial history and controls, res-
pectively. In the patients with a family history of an-
eurysm, the frequency of the 4G-allele differed
significantly from that of either patients with no his-
tory of aneurysm or control subjects. The current
study is much larger than these previous studies and
provides no evidence that the frequency of the
4G4 5G PAI-1 polymorphism is altered for patients
with AAA. However, all the findings are consistent
with the hypothesis that aneurysm growth is fastest
among patients of 5G5G genotype.
The 4G PAI-1 allele is associated with high PAI-1
concentrations in plasma. High plasma concentra-
tions of PAI-1 inhibit plasmin activity and impair
fibrinolysis. A previous study of just 61 patients
with septic shock associated with major trauma
showed a trend for poor survival for patients of
4G4G genotype.15 Among these patients 11/19 (58%)
with 4G4G genotype, 8/29 (28%) patients with 4G5G
genotype and 2/13 (15%) patients with 5G5G geno-
type did not survive. Interestingly, the patients of
4G4G genotype also had the highest circulating con-
centrations of the inflammatory cytokines interleukin-
1 and TNF-a in the early hospital course soon after
trauma. It was suggested that in the 4G4G patients,
the high circulating cytokine concentrations were an
inflammatory over-response to impaired fibrinolysis
and that the combination of impaired fibrinolysis
and overwhelming inflammatory response contribu-
ted to the poor outcome.15 The systemic response to
a major surgical response such as open AAA repair is
well established and includes the release of the in-
flammatory cytokines interleukin-1b and TNF-a.22,23
There also is evidence that fibrinolysis is impaired
following repair of ruptured AAA, with reduced ac-
tivity of both PAI-1 and tissue plasminogen activa-
tor.24 At the same time there was evidence for
intense thrombin generation.24 Similar, but less in-
tense changes were observed following elective AAA
repair and the authors concluded that the pro-
coagulant state was likely to contribute to the macro-
vascular and microvascular thromboses that underlie
myocardial infarction and multisystem organ failureEur J Vasc Endovasc Surg Vol 23, May 2002respectively.24 Hence, there is a scientific basis for the
hypothesis that patients of 5G5G PAI-1 genotype, who
have lower circulating concentrations of PAI-1, have
improved survival following open AAA repair com-
pared with those of 4G4G or 4G5G genotype.
Out findings support this hypothesis. Since there are
wide confidence intervals associated with 30-day
mortality, particularly in the 5G5G group, a much
larger study, of up to 1000 patients, might be necessary
to confirm the hypothesis.
In conclusion, the present work provides further
evidence that single polynucleotide polymorphisms
can predict outcome for patients with AAA. These
outcomes include cardiovascular mortality7 and mor-
tality after elective open repair. Since, the common
form of AAA is likely to be a polygenic disorder,
the evidence presented here for the 4G4 5G poly-
morphism in the PAI-1 promoter must be used in
conjunction with other relevant polymorphisms to in-
dicate the likely natural history associated with the
disorder. The observation, presented here, that
patients of 5G5G genotype have an improved progno-
sis after a major surgical procedure together with the
observation of Menges et al.15 that patients of 5G5G
genotype fare best after major trauma with sepsis
have widespread significance for vascular and gen-
eral surgery. These apparent effects of PAI-1 genotype
on survival should focus attention on fibrinolysis
following trauma or major surgical procedures, in-
cluding AAA repair.
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